Atlas Trials

Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer

Clinical trial NCT01823978 · COMPLETED

Trial details

NCT number
NCT01823978
Sponsor
Bellicum Pharmaceuticals
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Castrate Resistent Prostate Cancer
Start date
2013-04-01
Primary completion
2016-05-01
Enrollment
19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.